NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has entered into a collaboration agreement with Eli Lilly for biomarker discovery and validation using Exosome's EXO50 nucleic acid extraction kit.

Under the agreement, the financial terms of which were not disclosed, Lilly will gain early access to Exosome's technology to help it identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.